Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE542.001.6 (+0.3 % )
PREV CLOSE (Rs.) 540.40
OPEN PRICE (Rs.) 541.35
BID PRICE (QTY) 541.35 (272 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 53774
TODAY'S LOW / HIGH (Rs.)532.50 544.30
52 WK LOW / HIGH (Rs.)483.75 678
NSE541.15 0.6 (+0.11 % )
PREV CLOSE(Rs.) 540.55
OPEN PRICE (Rs.) 542.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 541.15 (149 )
VOLUME 1590101
TODAY'S LOW / HIGH(Rs.) 532.30 545.05
52 WK LOW / HIGH (Rs.)483.75 678.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 291.46
Dividend Yield(%) 0.55
TTM EPS (Rs.) 18.36
P/E Ratio 29.52
Book Value (Rs.) 186.99
Face Value (Rs.) 2
MCap (Rs. in Mn) 436686.40
Price/Earning (TTM) 21.44
Price/Sales (TTM) 3.89
Price/Book (MRQ) 2.90
PAT Margin (%) 12.83
ROCE (%) 14.03
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
11Feb02-11-2019$Cipla's arm completes first stage closing of Avenue Therapeutics Cipla's arm completes first

Cipla's wholly owned subsidiary -- InvaGen Pharmaceuticals Inc., USA has completed the first stage closing of Avenue Therapeutics Inc., transaction representing an acquisition of 33.3% stake in Avenue's capital stock on fully diluted basis on February 08, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla's wholly owned subsidiary -- InvaGen Pharmaceuticals Inc...
08Feb02-08-2019$Cipla informs about analyst meeting Cipla informs about analyst

Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, Cipla has informed about schedule of Analyst / Institutional Investors Meetings.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Securities and Exchange Board..
07Feb02-07-2019$Cipla gets final approval from USFDA for Tadalafil Tablets Cipla gets final approval fr

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (USFDA). The company’s Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Company’s Adcirca.

It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately $490 million for the 12-month period ending November 2018. The product is available for shipping immediately.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla has received final approval for its Abbreviated New Drug..
07Feb02-07-2019$Cipla gains on the bourses Cipla gains on the bourses

Cipla is currently trading at Rs. 533.20, up by 5.25 points or 0.99% from its previous closing of Rs. 527.95 on the BSE.

The scrip opened at Rs. 536.00 and has touched a high and low of Rs. 546.00 and Rs. 528.00 respectively. So far 119940 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 546.00 and Rs. 501.25 respectively. The current market cap of the company is Rs. 43060.34 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.60% and 23.69% respectively.

Cipla has reported a fall of 29.44% in its net profit at Rs 295.32 crore for the quarter ended December 31, 2018 as compared to Rs 418.54 crore for the same quarter in the previous year. Total income of the decreased by 3.28% at Rs 2912.15 crore for Q3FY19 as compared Rs 3010.89 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 17.06% in its net profit at Rs 332.20 crore for the quarter under review as compared to Rs 400.51 crore for the same quarter in the previous year. However, total income of the company increased by 3.01% at Rs 4086.07 crore for Q3FY19 as compared Rs 3966.75 crore for the corresponding quarter previous year.

Cipla is currently trading at Rs. 533.20, up by 5.25 points or..
07Feb02-07-2019$Cipla, Southern Petrochemicals Industries and Blue Star to see some action today Cipla, Southern Petrochemica

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (USFDA). According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately $490 million for the 12-month period ending November 2018. The product is available for shipping immediately.

Southern Petrochemicals Industries Corporation’s Plants at Tuticorin have been restarted and production resumed on February 02, 2019 after attending to repairs to critical equipment (Urea Reactor) and completing essential shut down jobs.

Blue Star has received an approval for the proposal to exit the Joint Venture, in view of cost overrun in the projects executed by Blue Star Oman Electro-Mechanical Company LLC (BSOEMC), the company's joint venture in Oman and unattractive business potential in Oman. The Board of the company at its meeting held on February 05, 2019, approved the same.

Tata Power Company’s wholly-owned subsidiary -- Tata Power Solar has launched a complete residential rooftop solution in Chennai. The residential rooftop solutions are expected to save up to Rs 50,000 annually for 25 years.

Fairchem Speciality has decided to incorporate wholly owned subsidiary company as ‘Public Limited Company’ and to make initial investment up to Rs 1,00,000 by way of subscription to Equity Share Capital of the said proposed subsidiary company. The Board of Directors of the company at its meeting held on February 05, 2019, decided the same.

Jai Corp has received an approval for further investments up to Rs 40.00 crore in suitable securities of wholly-owned Indian subsidiary companies as per the requirement of funds of those companies. The Board of the company at its meeting held on February 05, 2019, approved the same.

Torrent Power has received an approval for the issuance of Non-Convertible Debentures (NCDs) up to Rs 1000 crore in one or more tranches by way of Private Placement basis within the overall borrowing limits of the company. The Board of the company at its meeting held on February 05, 2019, approved the same.

Cipla has received final approval for its Abbreviated New Drug..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit2953.214685.2
Gross Profit 4115.1 19114
Operating Profit 5630.325304.3
Net Sales 28352114448.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Hester Biosciences (BSE)
 1408.00 (2.33%)
M.Cap ( in Cr)
1197.77
Ipca Laboratories (BSE)
 805.00 (3.87%)
M.Cap ( in Cr)
10171.34
Alkem Laboratories (BSE)
 1831.35 (1.56%)
M.Cap ( in Cr)
21896.54
Dr. Reddys Lab (BSE)
 2570.00 (0.51%)
M.Cap ( in Cr)
42677.64
Piramal Enterprises (BSE)
 2169.25 (0.40%)
M.Cap ( in Cr)
39922.92
Shareholding Pattern More
PROMOTERS 36.7 %
NON-INSTITUTION 23.69 %
FI/BANKS/INSURANCE 2.83 %
MUTUAL FUNDS/UTI 10.9 %
FII 0.61 %
GOVERNMENT 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested